The Australian medical sector is abuzz with the introduction of retatrutide, a novel dual GIP and GLP-1 receptor agonist showing remarkable results in clinical trials for managing obesity. This medication https://bookmarkplaces.com/story21690655/retatrutide-australia-a-emerging-prospect-for-weight-management